Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.
2.

Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer.

Park KW, Ahn JS, Park YS, Lee J, Kang JH, Park JO, Lim HY, Im YH, Kang WK, Park K, Lee SI.

Cancer Chemother Pharmacol. 2007 Jan;59(1):17-21. Epub 2006 May 24.

PMID:
16721549
3.

Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer.

Kim ST, Kang WK, Kang JH, Park KW, Lee J, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Im YH, Park K.

Br J Cancer. 2005 May 23;92(10):1850-4.

4.

Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes.

Park SH, Choi EY, Bang SM, Cho EK, Lee JH, Shin DB, Ki Lee W, Chung M.

Anticancer Drugs. 2005 Jul;16(6):621-5.

PMID:
15930889
5.

Phase II study of sequential treatment with S-1 and cisplatin for metastatic gastric cancer.

Baba E, Esaki T, Ariyama H, Mitsugi K, Morikita T, Fujishima H, Kusaba H, Nakano S, Akashi K.

Cancer Chemother Pharmacol. 2011 Sep;68(3):611-7. doi: 10.1007/s00280-010-1529-0. Epub 2010 Nov 30.

PMID:
21116623
6.

Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.

Honecker F, Kollmannsberger C, Quietzsch D, Haag C, Schroeder M, Spott C, Hartmann JT, Baronius W, Hempel V, Kanz L, Bokemeyer C.

Anticancer Drugs. 2002 Jun;13(5):497-503.

PMID:
12045461
7.

Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer: a multicenter phase II study.

Baek JH, Kim JG, Sohn SK, Kim DH, Lee KB, Song HS, Kwon KY, Do YR, Ryoo HM, Bae SH, Park KU, Kim MK, Lee KH, Hyun MS, Chung HY, Yu W.

J Korean Med Sci. 2005 Dec;20(6):966-70.

8.

Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.

Goel A, Grossbard ML, Malamud S, Homel P, Dietrich M, Rodriguez T, Mirzoyev T, Kozuch P.

Anticancer Drugs. 2007 Mar;18(3):263-71.

PMID:
17264757
9.

Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer.

Kucukzeybek Y, Dirican A, Erten C, Somali I, Can A, Demir L, Bayoglu IV, Akyol M, Medeni M, Tarhan MO.

Asian Pac J Cancer Prev. 2012;13(6):2771-4.

10.

A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.

Kim BG, Oh SY, Kwon HC, Lee S, Lee DM, Kim SG, Kim DK, Jang JS, Kim MC, Kim SH, Kim HJ.

Am J Clin Oncol. 2010 Jun;33(3):246-50. doi: 10.1097/COC.0b013e3181a650d4.

PMID:
19770628
11.

Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer.

Ilson DH.

Oncology (Williston Park). 2004 Dec;18(14 Suppl 14):22-5.

12.

Phase 1/11 study of bi-weekly irinotecan plus cisplatin in the treatment of advanced gastric cancer.

Koizumi W, Kurihara M, Satoh A, Takiuchi H, Tanabe S, Shimada K, Iwasaki R, Saigenji K.

Anticancer Res. 2005 Mar-Apr;25(2B):1257-62.

13.

Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma.

Ajani JA, Baker J, Pisters PW, Ho L, Mansfield PF, Feig BW, Charnsangavej C.

Oncology (Williston Park). 2002 May;16(5 Suppl 5):16-8.

14.

Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer.

Chitapanarux I, Tonusin A, Sukthomya V, Charuchinda C, Pukanhapan N, Lorvidhaya V.

Gynecol Oncol. 2003 Jun;89(3):402-7.

PMID:
12798702
15.

A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma.

Scott LC, Yao JC, Benson AB 3rd, Thomas AL, Falk S, Mena RR, Picus J, Wright J, Mulcahy MF, Ajani JA, Evans TR.

Cancer Chemother Pharmacol. 2009 Jan;63(2):363-70. doi: 10.1007/s00280-008-0746-2. Epub 2008 Apr 9.

PMID:
18398613
16.

Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancer.

Ueda S, Hironaka S, Boku N, Fukutomi A, Yoshino T, Onozawa Y.

Gastric Cancer. 2006;9(3):203-7.

PMID:
16952039
17.

Feasibility study of biweekly CPT-11 plus CDDP for S-1- and paclitaxel-refractory, metastatic gastric cancer.

Yoshida T, Yoshikawa T, Tsuburaya A, Kobayashi O, Hasegawa S, Osaragi T, Sairenji M.

Anticancer Res. 2006 Mar-Apr;26(2B):1595-8.

18.

Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.

Jung JY, Kwon JH, Kim JH, Song HH, Kim I, Lee KS, Kim HJ, Zang DY, Ahn JS, Lee JA, Park YI.

Oncol Rep. 2009 Feb;21(2):523-9.

PMID:
19148531
19.

Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801/BIRIP trial).

Higuchi K, Tanabe S, Shimada K, Hosaka H, Sasaki E, Nakayama N, Takeda Y, Moriwaki T, Amagai K, Sekikawa T, Sakuyama T, Kanda T, Sasaki T, Azuma M, Takahashi F, Takeuchi M, Koizumi W; Tokyo Cooperative Oncology Group, Tokyo, Japan.

Eur J Cancer. 2014 May;50(8):1437-45. doi: 10.1016/j.ejca.2014.01.020. Epub 2014 Feb 20.

PMID:
24560487
20.

Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.

Sato Y, Takayama T, Sagawa T, Takahashi Y, Ohnuma H, Okubo S, Shintani N, Tanaka S, Kida M, Sato Y, Ohta H, Miyanishi K, Sato T, Takimoto R, Kobune M, Yamaguchi K, Hirata K, Niitsu Y, Kato J.

Cancer Chemother Pharmacol. 2010 Sep;66(4):721-8. doi: 10.1007/s00280-009-1215-2. Epub 2009 Dec 30.

PMID:
20041328

Supplemental Content

Support Center